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MULTIPLE organ failure (MOF) induced by mesen-
teric infarction is associated with a high mortality
rate. This study reports eicosanoid and cytokine
levels in the blood of three atherosclerotic pa-
tients who ultimately died from MOF induced by
mesenteric infarction. High plasma levels of 6-
keto-prostaglandin (PG) F1a (the stable metabolite
of PGI2), interleukin (IL)-6 and IL-8 are observed
whereas plasma tumour necrosis factor alpha
(TNFa), TxB2 (the stable metabolite of TxA2),
PGE2, leukotrienes (LT)B4 and LTC4, and whole
blood platelet-activating factor levels are not dif-
ferent from values obtained in similarly severe
atherosclerotic patients. This short report ques-
tioned the clinical involvement of TNFa during
such a pathology where a persistent translocation
of endotoxin has been observed through the gut
endothelial barrier. Activation of phospholipase
A2 is suggested by the increase in the stable
metabolite of PGI2 and might be by itself or
through lipidic metabolites, a major systemic
stimulus of IL-6 and IL-8 production.
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Introduction
Mesenteric infarction is associated with a high
mortality rate. Lactic acidosis, hyperthermia,
acute respiratory distress syndrome and cardio-
genic shock are common consequences of this
disease suggesting the plasma release of factors
inducing multiple organ failure (MOF). Eico-
sanoids [such as prostaglandins (PG) E2 and I2,
leukotrienes (LT) B4 and C4 and platelet-activat-
ing factor (PAF)] and cytokines [such as tumour
necrosis factor alpha (TNFa), interleukin (IL)-6
and IL-8] could be involved in this process
because of their cardiovascular and proin￿am-
matory effects. Phospholipase A2 (the enzyme
leading to eicosanoid production) is stimulated
in experimental mesenteric ischaemia-reperfu-
sion syndrome.1 On the other hand, in animal
and human mesenteric ischaemia, the bacterial
translocation might trigger TNFa then IL-6 and
IL-8 plasma release.2 Finally, the production and
action of cytokines and eicosanoids are linked
to each other. Thus we have assessed eico-
sanoid and cytokine plasma levels in three
patients with mesenteric infarction before MOF
development compared with 10 atherosclerotic
patients.
Patients and Methods
The ￿rst patient (71 years old) developed a
jejunal infarction 48 h after a transurethral
resection of the prostate which was compli-
cated by myocardial ischaemia and supraventri-
cular arrhythmia. Treatment included anti-
arrhythmic drugs (amiodarone and deslanoside),
and venous thrombosis prophylaxis with a low
molecular weight heparin (dalteparine 5000 IU).
At blood sampling, blood pressure (120/
80 mmHg) and heart rate (100 cpm) were stable
but hyperthermia (388 C), hyperleukocytosis
(13 g.l 1) and metabolic acidosis (pH 7.31,
HCO3 18.1 mmol.l 1) were present. The
prothrombin time (10 s) and the platelet count
(359 g.l 1) were normal. A cardiogenic shock
occurred in the early postoperative period and
the patient died 34 days later of a MOF
syndrome.
The second patient (87 years old) suffered
from angina pectoris, non-insulin-dependent
diabetes mellitus and chronic obstructive
pulmonary disease. His right leg had been
amputed 2 days before and he was taking orally
a calcium inhibitor (nifedipine) and transdermal
trinitrine. At blood sampling arterial pressure
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stable but hyperthermia (38.58 C), polypnoea,
and severe lactic acidosis (pH 7.15, HCO3
8.8 mmol.l 1, blood lactates 14.4 mmol.l 1)
were present. Activated partial thrombin time
(30.7 s), prothrombin time (14 s) and platelet
count (257 g.l 1) were normal. Surgery revealed
a partial small bowel necrosis without occlusion
of the mesenteric artery and vein. The patient
died 19 h later from a severe cardiogenic shock.
The third patient (76 years old) had a mitral
prosthesis and atria ￿brillation treated by oral
anticoagulant (￿uindone). At blood sampling,
blood pressure (150/80 mmHg) and heart rate
(105 cpm) were stable but associated with
hyperthermia (398 C), metabolic acidosis (pH
7.38, HCO3 16 mmol.l 1) and hyperleuko-
cytosis (25.5 g.l 1). Coagulation parameters
demonstrated the biological ef￿ciency of the
anticoagulant treatment without associated
disseminated intravascular coagulation (pro-
thrombin timeINR 19% , factor V level
133% ). Laparotomy revealed a necrosis of the
whole digestive tract and the patient died 19 h
later from cardiogenic shock.
The control patients (mean age 69 [26] years)
(eight males/two females) suffered from a
severe atherosclerotic disease and were sched-
uled for coronary artery bypass grafting. Their
treatment included trinitrine or calcium inhibi-
tors. All patients had their aspirin and angioten-
sin converting enzyme inhibitors stopped for 1
week and 3 days respectively at the time of
blood sampling for which they gave written
informed consent.
Blood samples were obtained at the time of
diagnosis of mesenteric infarction during lapar-
otomy before MOF occurred. Blood PAF was
ethanol extracted, processed and assayed by
platelet aggregation.3 Plasma PAF acetylhydro-
lase activity (the enzyme which inactivates PAF)
was measured by the degradation of 3H-PAF .4
Cytokines and other eicosanoids were deter-
mined in plasma with speci￿c enzymo-immuno-
sorbent assay (EIA) after a three- and ￿ve-fold
dilution in EIA buffer (TEBU and Cayman
Chemicals, sensitivity 2 and 5 pg.ml 1, respec-
tively). The results (shown as individual values
and median [range] for the control group) are
compared with those of the control patient by a
Mann± Whitney U-test.
Results and Discussion
The results are presented in Table 1. High
plasma IL-6, IL-8 and 6-keto-PGF1a (the stable
metabolite of PGI2) levels were found in these
three mesenteric infarcted patients suggesting a
role for these mediators in the MOF syndrome
which occurred later. High IL-6 and IL-8 levels
are associated with a poor prognosis during
sepsis syndrome where TNFa is supposed to
trigger their synthesis. In these three patients,
TNFa was not detectable suggesting that its
production was not clinically relevant because
it was not as high as during sepsis despite
a theoretical persistent endotoxic stimulus.2
TNFa independent pathway of IL-6 and IL-8
synthesis have already been described during
sepsis as well as during experimentally induced
cancer. However, the role of TNFa as a med-
iator inducing IL-6 and IL-8 synthesis cannot be
de￿nitively excluded. Indeed, the ￿xation of
TNFa on soluble receptors and/or its transient
release may lead to dif￿culties in its detection
in blood. No elevated blood PAF levels were
observed in these patients while PAF is pro-
duced by the intestinal tract after experimental
hypoxia and PAF antagonists reduced mesen-
teric ischaemia-induced mortality in animals.5
These low PAF levels did not result from an
increased PAF degradation as shown by the
Table 1. Blood platelet-activating factor (PAF), plasma TNFa, IL-6, IL-8, LTB4, LTC4, 6-
keto-PGF1a, TxB2, PGE2 (pg.ml 1) and acetylhydrolase activity (nmol.min 1.ml 1) in
patients with mesenteric infarction (individual values) compared with atherosclerotic
patients (median [range]) by Mann± Whitney U-tests
Patient 1 Patient 2 Patient 3 Control patients
(n 10)
P
TNFa 0 0 0 0 [0] 1
IL-6 980 3800 600 0 [18] 0.01
IL-8 160 210 225 36 [135] 0.01
PAF 175 220 50 113 [49] 0.55
Acetylhydrolase 10.4 51.7 36.0 65.9 [49.3] 0.35
6 keto PGF1a 3400 2600 2300 240 [620] 0.01
TxB2 125 450 5 72.5 [500] 0.67
PGE2 760 180 1880 220 [848] 0.35
LTB4 0 0 0 0 [0] 0.32
LTC4 0 0 0 0 [128] 0.26
76 Mediators of In¯ ammation ´ Vol 6 ´ 1997
N. Nathan, Y. Denizot and P. Feissnormal PAF acetylhydrolase activity. The other
lipidic mediators were not detectable or were at
normal levels except for the stable metabolite
of PGI2 which may be secreted chie￿y from
vascular endothelium after hypoxia. The levels
of TxB2 in plasma were similar to those of
severe atherosclerotic patients. TxA2 plasma
levels are supposed to be originated chie￿y
from activated platelets. The absence of hae-
mostasis impairment in our patients may, in
part, explain the similar values of their TxB2
blood levels compared with those of athero-
sclerotic patients. PGI2 is a potent vasodilator
whereas TxA2 highly vasoconstricts peripheral
vessels. The high PGI2± TxB2 ratio observed in
our patient could be considered as a protective
mechanism to counteract the mesenteric hypo-
perfusion.
The number of subjects in this study is small
due to dif￿culties in obtaining blood before
MOF occurrence. Indeed, the diagnosis of
mesenteric infarction is usually made late, at the
time of MOF . Nevertheless our results con￿rm
experimental data questioning the true role of
TNFa induced by endotoxinaemia as a trigger
for in￿ammatory reaction and MOF as it has
already been observed during sepsis.6 The
activation of phospholipase A2 and the subse-
quent release of eicosanoids which may in turn
stimulate IL-6 or IL-8 production are other ways
of research deserving further investigation in
humans.
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